David Weingeist
Scientific Director, Oncology Precision Medicine & Diagnostics Johnson & Johnson
David is the Global Dx Development Leader for the Bladder Cancer Team at Johnson & Johnson Innovative Medicine, where he is responsible for development of global diagnostic solutions in support of the bladder cancer precision medicine portfolio.
David received a bachelor’s degree in Chemical Engineering from Washington University in St. Louis and a master’s degree in BioScience Enterprise from Cambridge University. He earned his doctorate in Bioengineering from the Massachusetts Institute of Technology, where he conducted his graduate research developing a novel assay to measure DNA damage and repair kinetics. His professional experience prior to Johnson & Johnson Innovative Medicine includes seven years in life science strategy consulting with a focus in precision medicine and another five years at Roche Pharmaceuticals (Genentech and Foundation Medicine) in the personalized healthcare, global product strategy organization.
Seminars
- What are the key strategies to overcome barriers to widespread adoption of digital pathology? And how can organizations build the necessary infrastructure to support digital pathology at scale?
- What are the commercial challenges facing digital pathology as a companion diagnostic and how can companies address these obstacles?
- What are the current regulatory challenges in getting digital pathology technologies approved for use as CDx, and how can these be addressed moving forward?
- Reviewing strategies to address tissue insufficiency
- Showcasing urine based liquid biopsy for patient selection and monitoring
- Exploring a histopathology-based AI algorithm for FGFR detection
